Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
Inventor: Ranjit Ray, Ratna Ray, Arnab Basu and Yie-Hwa Chang
Liver fibrosis is a central feature of the majority of chronic liver injuries caused by metabolic, genetic, viral, and cholestatic diseases in humans. Fibrosis distorts the liver architecture (cirrhosis) and is associated with a marked disturbance of liver function that results in significant morbidity and mortality. Hepatic stellate cells (HSC), which compose about 15% of the total number of resident liver cells, are the main hepatic cell type involved in the development of liver fibrosis following injury.
Compositions and methods are described for selectively inhibiting the proliferation of stellate cells responsible for the development of fibrosis in the liver following injury. A novel protein present in conditioned media from immortalized hepatocytes appears to induce apoptosis and selectively kill liver stellate cells.
Application: Treatment of liver fibrosis
Keywords: Stellate cells, liver fibrosis, cirrhosis, apoptosis
Patent: U.S. Patent Application 10/888,962 (Filed: July 9, 2004)
Reference Number: SLU-1026